Valeria Santini
About
Valeria Santini is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Valeria Santini has authored 272 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 228 papers in Hematology, 142 papers in Genetics and 69 papers in Molecular Biology. Recurrent topics in Valeria Santini's work include Acute Myeloid Leukemia Research (202 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (84 papers) and Hemoglobinopathies and Related Disorders (49 papers). Valeria Santini is often cited by papers focused on Acute Myeloid Leukemia Research (202 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (84 papers) and Hemoglobinopathies and Related Disorders (49 papers). Valeria Santini collaborates with scholars based in Italy, United States and France. Valeria Santini's co-authors include Pierre Fenaux, Guillermo Sanz, Alan F. List, John F. Seymour, Eva Hellström‐Lindberg, Steven D. Gore, Ghulam J. Mufti, Lewis R. Silverman, C.L. Beach and Jay T. Backstrom and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.
In The Last Decade
Valeria Santini
257 papers receiving 7.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Valeria Santini Italy | 38 | 5.6k | 3.4k | 2.4k | 1.0k | 962 | 272 | 7.8k | ||
| Philippe Rousselot France | 46 | 4.7k 0.8× | 1.8k 0.5× | 2.7k 1.1× | 1.3k 1.2× | 1.3k 1.3× | 181 | 6.8k | ||
| Paresh Vyas United Kingdom | 52 | 5.1k 0.9× | 4.4k 1.3× | 1.8k 0.8× | 1.3k 1.3× | 1.1k 1.1× | 235 | 9.4k | ||
| Jeffrey Tyner United States | 46 | 2.9k 0.5× | 3.3k 1.0× | 2.1k 0.9× | 1.3k 1.3× | 435 0.5× | 238 | 7.1k | ||
| Michael Lübbert Germany | 60 | 7.2k 1.3× | 7.4k 2.2× | 2.2k 0.9× | 2.0k 2.0× | 1.6k 1.7× | 297 | 12.7k | ||
| Bruno Quesnel France | 47 | 3.6k 0.6× | 3.5k 1.0× | 1.9k 0.8× | 2.6k 2.6× | 691 0.7× | 202 | 8.1k | ||
| Soheil Meshinchi United States | 49 | 5.8k 1.0× | 4.2k 1.2× | 1.2k 0.5× | 1.4k 1.4× | 2.7k 2.8× | 328 | 8.9k | ||
| Stanley R. Frankel United States | 36 | 3.0k 0.5× | 5.2k 1.5× | 960 0.4× | 1.7k 1.7× | 1.1k 1.1× | 73 | 8.1k | ||
| Claus R. Bartram Germany | 48 | 4.1k 0.7× | 3.8k 1.1× | 2.1k 0.9× | 1.7k 1.7× | 2.9k 3.0× | 212 | 10.0k | ||
| Wei Tong United States | 34 | 1.7k 0.3× | 2.7k 0.8× | 1.8k 0.8× | 948 0.9× | 227 0.2× | 84 | 5.6k | ||
| Itaru Matsumura Japan | 39 | 2.0k 0.4× | 2.5k 0.7× | 1.2k 0.5× | 1.4k 1.4× | 233 0.2× | 216 | 5.5k |
Countries citing papers authored by Valeria Santini
Since
Specialization
Citations
This map shows the geographic impact of Valeria Santini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valeria Santini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valeria Santini more than expected).
Fields of papers citing papers by Valeria Santini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Valeria Santini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valeria Santini. The network helps show where Valeria Santini may publish in the future.
Co-authorship network of co-authors of Valeria Santini
This figure shows the co-authorship network connecting the top 25 collaborators of Valeria Santini. A scholar is included among the top collaborators of Valeria Santini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valeria Santini. Valeria Santini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Santini, Valeria, et al.. (2025). How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome. British Journal of Haematology. 207(1). 15–26.
2.
Geißler, Klaus, Zdeněk Kořı́stek, Teresa Bernal, et al.. (2024). Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. British Journal of Haematology. 205(5). 1734–1745.
3.
Santini, Valeria, Maximilian Stahl, & David A. Sallman. (2024). TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. American Society of Clinical Oncology Educational Book. 44(3). e432650–e432650.
4.
Zeidan, Amer M., Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2024). Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.. Journal of Clinical Oncology. 42(16_suppl). 6565–6565.
5.
Garcia‐Manero, Guillermo, Karen Yee, Francisca Hernández, et al.. (2024). Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.. Journal of Clinical Oncology. 42(16_suppl). 6509–6509.
6.
Onida, Francesco, Nico Gagelmann, Yves Chalandon, et al.. (2024). Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee. Blood. 143(22). 2227–2244.
7.
Olíva, Esther Natalie, Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2024). Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study. Blood. 144(Supplement 1). 3216–3216.
8.
Garcia‐Manero, Guillermo, Uwe Platzbecker, Valeria Santini, et al.. (2023). Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).. Journal of Clinical Oncology. 41(16_suppl). 7003–7003.
9.
Komrokji, Rami S., Valeria Santini, Pierre Fenaux, et al.. (2023). Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study. Blood. 142(Supplement 1). 194–194.
10.
Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2023). Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 37(11). 2314–2318.
11.
Shallis, Rory M., Naval Daver, Jessica K. Altman, et al.. (2022). TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 129(2). 175–180.
12.
Patnaik, Mrinal M. & Valeria Santini. (2021). Targeting ineffective hematopoiesis in myelodysplastic syndromes. American Journal of Hematology. 97(2). 171–173.
13.
Park, Sophie, Jean‐François Hamel, Andréa Toma, et al.. (2020). Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia Research. 99. 106472–106472.
14.
Santini, Valeria, David Valcárcel, Uwe Platzbecker, et al.. (2019). Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research. 25(23). 6976–6985.
15.
Madanat, Yazan F., Mikkael A. Sekeres, Sudipto Mukherjee, et al.. (2018). Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes. Blood. 132(Supplement 1). 1797–1797.
16.
Santini, Valeria. (2014). Identificazione del paziente con diagnosi di sindrome mielodisplastica. Recenti Progressi in Medicina. 105(3). 127–31.
17.
Gore, Steven D., Pierre Fenaux, Valeria Santini, et al.. (2013). A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 98(7). 1067–1072.
18.
Spinelli, Elena, Roberto Caporale, Francesca Buchi, et al.. (2012). Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients. Clinical Cancer Research. 18(11). 3079–3089.
19.
Visani, Giuseppe, Massimo Breccia, Antonella Gozzini, et al.. (2010). Dasatinib, even at low doses, is an effective second‐line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life‐based Italian multicenter retrospective study on 114 patients. American Journal of Hematology. 85(12). 960–963.
20.
Fenaux, Pierre, Ghulam J. Mufti, Eva Hellström‐Lindberg, et al.. (2009). Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. Journal of Clinical Oncology. 28(4). 562–569.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by Paresh Vyas Breakdown of academic impact, for papers by Jeffrey Tyner Breakdown of academic impact, for papers by Michael Lübbert Breakdown of academic impact, for papers by Bruno Quesnel Breakdown of academic impact, for papers by Soheil Meshinchi Breakdown of academic impact, for papers by Stanley R. Frankel Breakdown of academic impact, for papers by Claus R. Bartram Breakdown of academic impact, for papers by Wei Tong Breakdown of academic impact, for papers by Itaru Matsumura